Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The Web of Science (WoS) has ranked Iran first among Islamic countries in molecular and genetic technologies over the 10 years from 2000 to 2024.

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

New treatments based on biological molecules like RNA give scientists unprecedented control over how cells function. But delivering those drugs to the ...

Arrowhead Pharmaceuticals recently reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi drug candidate designed to silence both PCSK9 and APOC3 to address atherosclerotic ...

Researchers have found that a long-acting injection, given just twice a year alongside standard drugs. Blood pressure is one of the most common health problems worldwide, yet it remains difficult to ...

This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline.

Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature tell a very different story. Report: Claire Robinson ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...